Related Experiment Video
Updated: Jan 24, 2026
06:15
Author Spotlight: Anterior HR-OCT as a Non-Invasive Tool for Characterizing Ocular Surface Squamous Neoplasia
Published on: August 9, 2024
1.8K
Bronchioloalveolar neoplasia.
Hitoshi Kitamura1, Koji Okudela
1Department of Pathology, Graduate School of Medicine, Yokohama City University 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan. pathola@med.yokohama-cu.ac.jp
International Journal of Clinical and Experimental Pathology
|January 14, 2011
Summary
Bronchioloalveolar carcinoma (BAC) and atypical adenomatous hyperplasia (AAH) involve KRAS and EGFR gene mutations. Further research is needed on their causes, progression, and genetic predispositions.
Area of Science:
- Oncology
- Molecular Genetics
- Pulmonary Medicine
Background:
- Bronchioloalveolar carcinoma (BAC), a type of lung adenocarcinoma, originates from atypical adenomatous hyperplasia (AAH).
- KRAS and epidermal growth factor receptor (EGFR) gene mutations are crucial in AAH and BAC development.
- Targeted therapies, like EGFR tyrosine kinase inhibitors, show promise in treating BAC.
Purpose of the Study:
- To review current knowledge on the etiology of BAC and AAH.
- To discuss genetic/epigenetic alterations in AAH to BAC progression.
- To explore genetic backgrounds for multiple AAH/BAC occurrences.
Main Methods:
- Literature review of molecular genetics investigations.
- Discussion of existing research findings.
- Consideration of a murine pulmonary carcinogenesis model for future studies.
Main Results:
- KRAS and EGFR mutations are significant in AAH and BAC pathogenesis.
- Targeted therapies offer successful treatment options.
- Key unresolved issues include etiology, progression mechanisms, and genetic predispositions.
Conclusions:
- Despite advances, the etiology of AAH/BAC, progression drivers, and genetic factors remain areas for further investigation.
- Murine models may aid in addressing these complex questions in lung cancer research.
